RxDoctor Payments Data

Meghan Poole, MD

Internal Medicine · Madison, MSNPI 1114281680

Payments from drug & device makers

$4,579in general payments, 2019–2025

Across 297 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$624
  • Novo Nordisk$567
  • Johnson & Johnson$457
  • Abbott$428
  • Amgen$315
  • Takeda Pharmaceuticals U.S.A., Inc.$313
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,567100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,579 in reported general payments places this provider in the 85th percentile of 846 internal medicine providers in Mississippi.

See all internal medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$71,426
Medicare patients
140
Services billed
1,436

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$82,331
MounjaroTirzepatide68$81,991
LinzessLinaclotide53$48,674
EliquisApixaban33$35,870
XareltoRivaroxaban21$18,632
FarxigaDapagliflozin Propanediol12$10,930
MyrbetriqMirabegron12$9,838
Breo ElliptaFluticasone/Vilanterol14$8,284
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$6,506
Rosuvastatin Calcium307$3,232
SynthroidLevothyroxine Sodium44$2,702
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp11$2,175
Atorvastatin Calcium197$2,085
Duloxetine Hcl40$1,924
Omeprazole143$1,864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$567$82,33156 claims
Lilly USA, LLCMounjaro$193$81,99168 claims
AbbVieLinzess, Synthroid$624$51,37597 claims
PfizerEliquis$261$35,87033 claims
Johnson & JohnsonXarelto$457$18,63221 claims
AstraZenecaFarxiga$288$10,93012 claims
GSKBreo Ellipta$112$8,28414 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$1,700137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 internal medicine providers in Mississippi.

Other internal medicine in Madison

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →